ALX Oncology Holdings Inc. (ALXO) annual income statement — 8-year revenue, gross profit & net income history
ALX Oncology Holdings Inc. (ALXO) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.18M | 4.8M | 2.07M |
| Revenue Growth % | - | - | - | - | - | -100% | -75.35% | 132.03% | - |
| Cost of Goods Sold | 150K | 0 | 0 | 0 | 0 | 0 | 1.07M | 4.36M | 1.88M |
| COGS % of Revenue | - | - | - | - | - | - | 90.95% | 90.91% | 90.95% |
| Gross Profit | -150K | 0 | 0 | 0 | 0 | 0 | 107K | 436K | 187K |
| Gross Margin % | - | - | - | - | - | - | 9.05% | 9.09% | 9.05% |
| Gross Profit Growth % | - | - | - | - | - | -100% | -75.46% | 133.16% | - |
| Operating Expenses | 82.64M | 104.02M | 142.47M | 170.28M | 127.44M | 83.56M | 43.77M | 19.62M | 13.87M |
| OpEx % of Revenue | - | - | - | - | - | - | 3703.05% | 409.07% | 671.07% |
| Selling, General & Admin | 20.96M | 23.85M | 26.09M | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.6M |
| SG&A % of Revenue | - | - | - | - | - | - | 1252.88% | 69.08% | 125.83% |
| Research & Development | 61.83M | 77M | 116.37M | 141.79M | 98.4M | 60.17M | 28.96M | 16.31M | 11.27M |
| R&D % of Revenue | - | - | - | - | - | - | 2450.17% | 339.99% | 545.23% |
| Other Operating Expenses | -150K | 3.17M | 0 | 0 | 0 | 0 | 0 | 0 | -2K |
| Operating Income | -82.55M | -104.02M | -142.47M | -170.28M | -127.44M | -83.56M | -43.66M | -19.18M | -13.68M |
| Operating Margin % | - | - | - | - | - | - | -3693.99% | -399.98% | -662.02% |
| Operating Income Growth % | - | 26.99% | 16.33% | -33.62% | -52.52% | -91.36% | -127.61% | -40.19% | - |
| EBITDA | -82.1M | -103.31M | -141.59M | -169.44M | -127.09M | -83.5M | -43.46M | -18.75M | -13.25M |
| EBITDA Margin % | - | - | - | - | - | - | -3676.9% | -391.03% | -641.17% |
| EBITDA Growth % | 32.04% | 27.03% | 16.43% | -33.32% | -52.2% | -92.14% | -131.74% | -41.51% | - |
| D&A (Non-Cash Add-back) | 454K | 706K | 872K | 836K | 342K | 51K | 202K | 429K | 431K |
| EBIT | -61.8M | -100.09M | -133.12M | -159.24M | -123.18M | -83.47M | -43.66M | -19.19M | -13.69M |
| Net Interest Income | 1.44M | 2.36M | 7.64M | 9.08M | 4.04M | -12.91K | -811K | -21K | 0 |
| Interest Income | 4.07M | 3.96M | 9.37M | 10.65M | 4.28M | 91 | 0 | 0 | 0 |
| Interest Expense | 837K | 1.6M | 1.73M | 1.56M | 238K | 13K | 811K | 21K | 0 |
| Other Income/Expense | 1.66M | 2.33M | 7.62M | 9.47M | 4.02M | 71K | -1.84M | -26K | -2K |
| Pretax Income | -80.89M | -101.69M | -134.85M | -160.81M | -123.42M | -83.48M | -45.5M | -19.21M | -13.69M |
| Pretax Margin % | - | - | - | - | - | - | -3849.32% | -400.52% | -662.12% |
| Income Tax | 0 | 0 | 0 | 0 | 64K | -21K | 241K | 34K | 45K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.05% | 0.03% | -0.53% | -0.18% | -0.33% |
| Net Income | -80.89M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Net Margin % | - | - | - | - | - | - | -3869.71% | -401.23% | -664.3% |
| Net Income Growth % | 30.61% | 24.59% | 16.14% | -30.23% | -47.95% | -82.47% | -137.7% | -40.14% | - |
| Net Income (Continuing) | -80.89M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.60 | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.63 |
| EPS Growth % | 41.36% | 26.36% | 31.02% | -23.43% | -46.38% | -61.72% | -45.45% | -39.68% | - |
| EPS (Basic) | - | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.63 |
| Diluted Shares Outstanding | 135.64M | 53.66M | 52.17M | 42.99M | 40.7M | 40.31M | 39.84M | 21.95M | 21.95M |
| Basic Shares Outstanding | 135.64M | 53.66M | 52.17M | 42.99M | 40.7M | 40.31M | 39.84M | 21.95M | 21.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ALXO stock.
For fiscal year 2025, ALX Oncology Holdings Inc. (ALXO) reported total revenue of $0.0M. This represents a 100.0% decline compared to $2.1M in 2018.
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $101.7M for the fiscal year ending 2025.